Plain-English translation of NCT07528352 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a two-step approach for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or stopped responding to earlier treatments. First, you would receive five days of radiation therapy to help shrink cancer in certain areas. Then you would receive one of two bispecific antibody medications— or —which are designed to help your immune system recognize and fight cancer cells. The study wants to understand how safe and well-tolerated this combination is.
Many people with this type of lymphoma run out of standard treatment options when their cancer returns or resists earlier therapies. This trial is exploring whether combining radiation with this new medication approach might help patients who have limited other choices.
You likely qualify if…
You likely don't qualify if…
You would first receive five consecutive days of radiation therapy targeted at up to three areas of your cancer. Immediately after that radiation course ends, you would begin receiving one of the two bispecific antibody medications ( or ), which will be given as injections or infusions over a period of time. The study will closely monitor your health with blood tests, physical exams, and imaging scans to check both how well the treatment works and what side effects you experience. The study is enrolling 12 people total and is currently recruiting participants.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States